Skip to main content

Advertisement

Table 1 Patient characteristics

From: Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid

Characteristic No.
Median age/years (range) 73 (59–87)
Gender (n=)
Male/female 19/5
Diagnosis (FAB) (n=)
RAEB 8
RAEB-T 3
CMML 2
AML 11
Diagnosis (WHO) (n=)
RAEB II 4
CMML II 2
AML, de novo 6
sAML/MDS 7
AML/MDS, therapy-related 5
IPSS-risk group (n=)
Intermediate II 5
High 9
Karyotype-risk (IPSS) (n=)
Good 9
Intermediate 4
Poor 11
Karyotype risk (AML1) (n=)
Good 0
Intermediate 12
Poor 12
Karyotype (n=)
Normal 7
Abnormal 17
Median marrow blast count (%) 18 (1–80)
Pre-treatment (n=)
Intensive chemotherapy 1
Hydroxyurea 3
LBH-589 3
VPA (+/− ATRA) 2
Growth factors 2
None 2
Transfusion dependency
Yes/no 19/5
Median WBC/μl 2,245 (400–32,000)
WBC > 10.000 (n=) 5
WBC < 1,800 20
WBC < 500 7
Median platelet count/μl 57,000 (5,000–252,000)
Platelets < 100,000 (n=) 17
Platelets < 30,000 9
  1. FAB French–American–British classification, WHO World Health organization classification, IPSS International Prognostic Scoring System, AML acute myeloid leukemia, VPA valproic acid, ATRA all-trans retinoic acid, WBC white blood count. 1 Grimwade 1998